Aarti Pharmalabs Limited (NSE: AARTIPHARM)
India
· Delayed Price · Currency is INR 696.10
+5.30 (0.77%)
Sep 6, 2024, 3:30 PM IST
Aarti Pharmalabs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
| Revenue | 19,497 | 18,526 | 19,452 | 11,999 | - | - |
| Revenue Growth (YoY) | 0.18% | -4.76% | 62.11% | - | - | - |
| Cost of Revenue | 11,281 | 10,608 | 12,046 | 7,470 | - | - |
| Gross Profit | 8,216 | 7,918 | 7,406 | 4,529 | - | - |
| Selling, General & Admin | 1,508 | 1,448 | 1,349 | 852.03 | - | - |
| Other Operating Expenses | 2,732 | 2,609 | 2,637 | 1,608 | 0.05 | 0.19 |
| Operating Expenses | 5,002 | 4,790 | 4,611 | 2,881 | 0.05 | 0.19 |
| Operating Income | 3,214 | 3,128 | 2,795 | 1,648 | -0.05 | -0.19 |
| Interest Expense | -178.76 | -172.15 | -210.52 | -3.4 | - | - |
| Interest & Investment Income | 30.74 | 30.74 | 21.87 | 24.84 | - | - |
| Other Non Operating Income (Expenses) | 28.81 | 11.49 | 1.85 | -116.1 | - | - |
| EBT Excluding Unusual Items | 3,095 | 2,998 | 2,608 | 1,554 | -0.05 | -0.19 |
| Gain (Loss) on Sale of Assets | 0.19 | 0.19 | -0.58 | 0.21 | - | - |
| Other Unusual Items | 6.53 | 6.53 | - | - | - | - |
| Pretax Income | 3,102 | 3,005 | 2,608 | 1,554 | -0.05 | -0.19 |
| Income Tax Expense | 849.3 | 835.9 | 672.78 | 331.29 | - | - |
| Net Income | 2,253 | 2,169 | 1,935 | 1,223 | -0.05 | -0.19 |
| Net Income to Common | 2,253 | 2,169 | 1,935 | 1,223 | -0.05 | -0.19 |
| Net Income Growth | 19.35% | 12.10% | 58.28% | - | - | - |
| Shares Outstanding (Basic) | 91 | 91 | 91 | 91 | 0 | 0 |
| Shares Outstanding (Diluted) | 91 | 91 | 91 | 91 | 0 | 0 |
| Shares Change (YoY) | 0.04% | 0.01% | - | 36150.40% | - | - |
| EPS (Basic) | 24.85 | 23.93 | 21.35 | 13.49 | -0.18 | -0.75 |
| EPS (Diluted) | 24.85 | 23.93 | 21.35 | 13.49 | -0.18 | -0.75 |
| EPS Growth | 19.30% | 12.08% | 58.27% | - | - | - |
| Free Cash Flow | - | 607.5 | 1,480 | -1,849 | - | -0.19 |
| Free Cash Flow Per Share | - | 6.70 | 16.33 | -20.40 | - | -0.75 |
| Dividend Per Share | - | 3.000 | 2.000 | - | - | - |
| Dividend Growth | - | 50.00% | - | - | - | - |
| Gross Margin | 42.14% | 42.74% | 38.07% | 37.74% | - | - |
| Operating Margin | 16.49% | 16.88% | 14.37% | 13.74% | - | - |
| Profit Margin | 11.55% | 11.71% | 9.95% | 10.19% | - | - |
| Free Cash Flow Margin | - | 3.28% | 7.61% | -15.41% | - | - |
| EBITDA | 3,973 | 3,860 | 3,421 | 2,069 | - | - |
| EBITDA Margin | 20.38% | 20.84% | 17.58% | 17.25% | - | - |
| D&A For EBITDA | 759.08 | 732.35 | 625.43 | 421.19 | - | - |
| EBIT | 3,214 | 3,128 | 2,795 | 1,648 | -0.05 | -0.19 |
| EBIT Margin | 16.49% | 16.88% | 14.37% | 13.74% | - | - |
| Effective Tax Rate | 27.38% | 27.82% | 25.80% | 21.32% | - | - |
| Revenue as Reported | 19,564 | 18,575 | 19,476 | 12,025 | - | - |
| Advertising Expenses | - | 64.11 | 51.61 | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.